
晚期乳腺癌维持化疗方案
方案 GT方案
将转移性乳腺癌患者,6程GT方案肿瘤控制良好的患者,随机分配至继续GT方案维持治疗组或停药观察组。

方案评价

续表

点评
转移性乳腺癌患者,GT方案控制良好的情况下,继续延长化疗可进一步延长患者的生存,总体不良事件耐受较好,对患者的生活质量无明显影响。因此,对于一些肿瘤控制良好、全身情况好、化疗耐受性好的患者可选择性延长化疗周期。
(安 欣 史艳侠)
参考文献
[1] PARK YH,JUNG KH,IM SA,et al.Phase Ⅲ multicenter randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy:KCSG-BR07-02.J Clin Oncol,2013,31(14):1732-1739.
[2] PARK YH,JUNG KH,IM SA,et al.Quality of life(QoL)in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine(PG)chemotherapy:results from phase Ⅲmulticenter,randomized trial of maintenance chemotherapy versus observation(KCSG-BR07-02).Breast Cancer Res Treat,2015,152(1):77-85.